Molecular target
α1-Adrenergic Receptor
Postsynaptic adrenergic receptor; agonism causes vasoconstriction. Blockade is associated with hypotension and is a side-effect signature of several psychotropics (atypical antipsychotics, trazodone) and a deliberate target in BPH and hypertension management.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on α1-Adrenergic Receptor
These medications have α1-Adrenergic Receptor among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on α1-Adrenergic Receptor
Each plant below contains a named compound documented to act on α1-Adrenergic Receptor. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- RuscogeninSteroidal saponin
Preclinical data suggest ruscogenin may promote venoconstriction via adrenergic (α1-adrenergic) pathways and exert anti-inflammatory effects through NF-κB and COX-2 modulation. Clinical translation of these specific mechanisms has not been fully established.
- NeoruscogeninSteroidal saponin
Shares proposed venoconstrictive and anti-inflammatory mechanism with ruscogenin; preclinical evidence only for discrete receptor-level activity.
- Ephedrinephenethylamine alkaloid
Indirect-acting sympathomimetic (releases norepinephrine from sympathetic nerve terminals) plus direct α1, β1, β2 adrenergic agonism. The combination produces vasoconstriction, increased cardiac output, and bronchodilation — therapeutic for bronchospasm and decongestion but at significant cardiovascular cost.
- Pseudoephedrinephenethylamine stereoisomer
Stereoisomer of ephedrine with greater nasal-decongestant selectivity — the basis for FDA-permitted single-ingredient pseudoephedrine OTC products (Sudafed). Lower cardiovascular impact than ephedrine but still meaningful at high dose.
- p-Synephrinephenethylamine
Selective β3-adrenergic agonist with mild α1 activity — promotes lipolysis in adipose tissue. Doesn't cross the blood-brain barrier as readily as ephedrine, but vascular α1 activity is the source of cardiovascular safety concerns.
- QuinidineQuinoline alkaloid (stereoisomer of quinine)
Shares the antiplasmodial haem polymerisation inhibition mechanism with quinine. As a pharmaceutical agent, quinidine is classified as a class Ia antiarrhythmic: studies describe blockade of voltage-gated sodium channels (prolonging action potential), L-type calcium channel antagonism, and α1-adrenergic blocking activity. These cardiac effects are relevant to drug interaction risk.